Editas Medicine (EDIT) Misses Q2 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. REGN
4. LITE
5. ABBV
6. MRVL
7. PLTR
8. CL
9. LYB
10. TFII

Go back to Editas Medicine (EDIT) Misses Q2 EPS by 15c

Editas Medicine Announces Second Quarter 2018 Results and Update

August 6, 2018 4:05 PM EDT

Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States

Plan to file EDIT-101 Investigational New Drug (IND) application in October 2018

Strong balance sheet to advance Company through multiple value inflection points

CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the second quarter ended June 30, 2018, and provided an update on recent... More